Research programme: MEK inhibitors - Bayer HealthCare
Latest Information Update: 19 Jul 2018
Price :
$50 *
At a glance
- Originator Valeant Pharmaceuticals International
- Developer Bayer HealthCare
- Class Small molecules
- Mechanism of Action Mitogen-activated protein kinase kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; Inflammation
Most Recent Events
- 13 Jul 2018 Valeant Pharmaceuticals International is now called Bausch Health Companies
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA (PO)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Inflammation in USA (PO)